Journal of Cardiac Failure最新文献

{"title":"Reprieve System for the Treatment of Patients With Acute Decompensated Heart Failure","authors":"JUAN B. IVEY-MIRANDA MD , VEENA S. RAO PhD , TAMAZ SHABURISHVILI MD , IVLITA VERULAVA MD , NINA KHABEISHVILI MD , MARK C. PETRIE MD , JAVED BUTLER MD, MPH, MBA , JULIO NUNEZ MD, PhD , JAN BIEGUS MD, PhD , PIOTR PONIKOWSKI MD, PhD , KEVIN DAMMAN MD, PhD , SEAN P. COLLINS MD , JEFFREY M. TESTANI MD, MTR , ZACHARY L. COX PharmD","doi":"10.1016/j.cardfail.2025.02.002","DOIUrl":"10.1016/j.cardfail.2025.02.002","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 7","pages":"Pages 1085-1089"},"PeriodicalIF":6.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Ketosis for Heart Failure: A State-of-the-Art Review","authors":"NANDAN KODUR BS, ,&nbsp;CHRISTOPHER NGUYEN PhD, ,&nbsp;W. H. WILSON TANG MD,","doi":"10.1016/j.cardfail.2025.01.028","DOIUrl":"10.1016/j.cardfail.2025.01.028","url":null,"abstract":"<div><div>Heart failure is characterized by an energy-deprived heart, and in recent years it has been found that the failing heart increases ketone body oxidation to meet its energy demands. Accumulating evidence suggests that this metabolic adaptation is cardioprotective, suggesting that interventions that boost blood ketone levels could aid the failing heart. Indeed, multiple small clinical trials with short-term follow up have demonstrated that supplying the failing heart with exogenous ketone bodies may improve myocardial function across various manifestations of heart failure. As such, therapeutic ketosis, which is a metabolic state in which blood ketone levels are mildly elevated, could have great potential to ameliorate heart failure. Therapeutic ketosis can be achieved endogenously via exercise or dietary practices, exogenously via supplementation with ketone bodies, or pharmacologically via treatment with a sodium-glucose cotransporter-2 inhibitor. Although ketosis-inducing practices cannot be routinely recommended to patients with heart failure at this time due to a lack of robust data regarding the long-term benefits and risks, anecdotal evidence suggests that some patients have begun to adopt ketosis-inducing practices, so it is important for clinicians to be aware of how to manage patients optimally when they are in therapeutic ketosis. In this review, we discuss myocardial ketone metabolism in heart failure, the current evidence for therapeutic ketosis in patients with heart failure, a framework to distinguish between therapeutic ketosis and the pathologic state of ketoacidosis, and practical considerations for managing patients adhering to ketosis-inducing practices.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 7","pages":"Pages 1051-1061"},"PeriodicalIF":6.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary Artery Calcium Score; Another Tool to Predict Heart-Failure Mortality?","authors":"C.W. JONATHAN LEE MBBS ,&nbsp;JULIA GRAPSA MD, PhD","doi":"10.1016/j.cardfail.2025.05.010","DOIUrl":"10.1016/j.cardfail.2025.05.010","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 7","pages":"Pages 1016-1017"},"PeriodicalIF":6.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Beginner’s Mind –Reflections for the Trainee Through the Retiree","authors":"Anuradha Lala MD ,&nbsp;Robert J. Mentz MD","doi":"10.1016/j.cardfail.2025.06.004","DOIUrl":"10.1016/j.cardfail.2025.06.004","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 7","pages":"Pages 987-988"},"PeriodicalIF":6.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Heart Failure Medications in Fontan Circulation: A Systematic Review of Evidence and Gaps in Pharmacologic Strategy.","authors":"Ali Abdulkarim, Tarek Alsaied, Jef Van den Eynde, Neil Nero, Nicole Rush, Shahnawaz Amdani","doi":"10.1016/j.cardfail.2025.05.020","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.05.020","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: Design and Rationale of the PRAISE-MR Trial.","authors":"Sebastiaan Dhont, Sara Moura Ferreira, Xavier Galloo, Pieter Martens, Evelyne Meekers, Katrien Tartaglia, Sébastien Deferm, Lieven Herbots, Wilfried Mullens, Frederik H Verbrugge, Jan Verwerft, Philippe B Bertrand","doi":"10.1016/j.cardfail.2025.05.019","DOIUrl":"10.1016/j.cardfail.2025.05.019","url":null,"abstract":"<p><strong>Background: </strong>Secondary or functional mitral regurgitation (FMR) of atrial origin is prevalent in heart failure with preserved ejection fraction (HFpEF) and portends a worse clinical course. Unlike ventricular FMR, it lacks evidence-based treatment and is often overlooked. Sacubitril-valsartan may provide benefit in this HFpEF phenotype.</p><p><strong>Objective: </strong>To assess the impact of sacubitril-valsartan on exercise hemodynamics in patients with HFpEF and atrial FMR.</p><p><strong>Methods: </strong>This multicenter, prospective, randomized, open-label trial with blinded endpoint assessment enrolls patients with stable HFpEF and at least moderate FMR documented within 1 year prior to enrollment. Participants are randomly assigned to sacubitril-valsartan plus standard medical therapy or to standard therapy alone, consisting of a mineralocorticoid receptor antagonist and a sodium-glucose cotransporter-2 inhibitor. Cardiopulmonary exercise testing with echocardiography is performed at baseline and after 6 months, with interval 24-hour home blood pressure monitoring to ensure blood pressure control in both arms. The primary endpoint is the change in exercise-induced pulmonary hypertension, assessed by the change in the mean pulmonary arterial pressure to cardiac output slope. This slope reflects total pulmonary resistance driven by both pre- and postcapillary factors, capturing key HFpEF features, including myocardial properties, vascular remodeling and the overall impact of (dynamic) atrial FMR. Secondary endpoints include changes in FMR severity, peak oxygen consumption, natriuretic peptide levels, left atrial size and function, and patient-reported outcomes. Prespecified adverse events include hypotension, renal failure, hyperkalemia, and angioedema.</p><p><strong>Conclusion: </strong>The PRAISE-MR (Sacubitril-Valsartan in Heart Failure with Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation) trial will evaluate whether sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, is beneficial in patients with HFpEF and atrial FMR.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144496782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients with Moderate to High-Risk CMV Serostatus.","authors":"Afsana Rahman, Changhee Lee, Salwa Rahman, Julia Baranowska, Cathrine M Moeller, Andrea Fernandez Valledor, Gal Rubenstein, Daniel Oren, Adel T Alnatour, Brain LaBarre, Kyung Taek Oh, David Bae, Jayant Raikhelkar, Dor Lotan, Ersilia M DeFilippis, Adil A Yunis, Justin Fried, Farhana Latif, Melana Yuzefpolskaya, Paolo C Colombo, Edward Lin, David T Majure, Kevin J Clerkin, Jason Choe, Gabriel Sayer, Nir Uriel","doi":"10.1016/j.cardfail.2025.05.017","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.05.017","url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus (CMV) infection post heart transplantation (HT) is associated with worse outcomes. Antiviral prophylaxis for at-risk patients is standard of care. Valganciclovir, the most commonly used antiviral, is associated with significant adverse events, particularly leukopenia. Letermovir is a CMV-specific anti-viral with a favorable side effect profile but its efficacy in HT recipients is unclear. This study aims to assess the safety and efficacy of letermovir for CMV prophylaxis in HT recipients.</p><p><strong>Methods: </strong>This single-center retrospective analysis included HT recipients at our center from January 2020-September 2023. Patients who were switched to letermovir for CMV prophylaxis for leukopenia/neutropenia on valganciclovir, and 1) remained on letermovir for at least 60 days or 2) developed CMV viremia on letermovir within 60 days of initiation were included. Primary endpoint was incidence of CMV viremia/disease during letermovir therapy. Secondary endpoints included changes in white blood cell (WBC) count, tacrolimus dosing, and clinically significant acute rejection.</p><p><strong>Results: </strong>Fifty-two patients received letermovir for an average of 8.2 months (range 1 to 35 months). Average time from transplant to letermovir initiation was 9.2 months, (range 0.9 to 77 months). Eight (15.4%) patients developed breakthrough CMV viremia on letermovir with a median viral load of 205 [IQR 142-367.5] copies/mL, and 4 of these patients were converted back to valganciclovir; overall 92.3% of patients completed therapy with letermovir. There were no episodes of suspected or biopsy-proven, CMV disease. Majority of patients (78%) required dose reductions of tacrolimus following letermovir initiation with no episodes of tacrolimus toxicity requiring hospitalization. WBC counts increased, on average, from 2.6 to 5.3 × 10³ cells/μL, p <0.001.</p><p><strong>Conclusions: </strong>Letermovir holds promise as an effective and safe alternative to valganciclovir for CMV prophylaxis in HT recipients.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144496783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Patient Experience: A Qualitative Study of Heart Failure Online Support Groups.","authors":"Zara Latif, Beier Nelson, Aditya Tummala, Tracy T Makuvire, Ersilia M Defilippis, Pablo Quintero Pinzon, Haider J Warraich","doi":"10.1016/j.cardfail.2025.05.018","DOIUrl":"10.1016/j.cardfail.2025.05.018","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights From Around the World: the 2025 Japanese Heart Failure Guidelines.","authors":"Jozine M Ter Maaten, Randall C Starling","doi":"10.1016/j.cardfail.2025.06.003","DOIUrl":"10.1016/j.cardfail.2025.06.003","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Placing Attention on Behaviors to Reduce Disparities in Heart Failure Care.","authors":"Mary E Acosta, Manreet Kanwar, Nikhil Narang","doi":"10.1016/j.cardfail.2025.06.002","DOIUrl":"10.1016/j.cardfail.2025.06.002","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}